Schizophrenia News

Recent findings indicated that veterans with schizophrenia who misused alcohol were less likely to utilize health care services than those who did not misuse alcohol; however, they reported poorer psychotic symptoms and quality of life.

Newron Pharmaceuticals recently presented data that indicated efficacy of Evenamide, a sodium channel blocker, as an adjunctive treatment for schizophrenia.

Abnormal neural responses at age 14 years may predict mood fluctuations and psychotic experiences at age 16 years among youth who report psychotic-like experiences.

Following mediocre efficacy of At Risk Mental State services, researchers developed an online individualized risk calculator for transdiagnostic prediction of psychosis in secondary mental health care.

Researchers at Emory University recently received a $3.1 million grant from the NIMH to study associations between 3q29 deletion syndrome and risk for schizophrenia and other neuropsychiatric disorders, such as intellectual disability, autism and anxiety.

Data presented at the International Congress on Schizophrenia Research indicated a higher dose of Aristada may be safe and effective for a two-month dose interval, potentially expanding dosing options of aripiprazole treatments.

Recent findings suggest that a simple hormone test may accurately identify depression or schizophrenia and distinguish between the two disorders.

Once-daily valbenazine, a selective vesicular monoamine transporter 2 inhibitor, significantly improved tardive dyskinesia in individuals with schizophrenia, schizoaffective disorder or mood disorder.

Rutgers University Behavioral Health Care recently opened a first-episode psychosis outpatient clinic in its Edison Metroplex location for individuals aged 15 to 35 years.

Allergan recently announced the FDA accepted a supplemental New Drug Application for Vraylar as maintenance treatment for adults with schizophrenia.